RBC starts European pharma stocks coverage, prefers these 2 names
RBC initiated coverage of five European pharma companies, rating Roche (RHHBY) and AstraZeneca (AZN) Outperform with price targets of 400 CHF and 14,500 pence, respectively. Novartis (NOVN), GSK (GSK), and Sanofi (SNY) were rated Sector Perform. Analysts highlighted Roche's strong pipeline and AstraZeneca's undervaluation.
How this was made
The 30-second read
Why it matters
Analyst initiations provide fresh guidance and valuation benchmarks, influencing short-term sentiment.
Market read
The new coverage may prompt revaluation of European pharma stocks, especially Roche and AstraZeneca.
What to watch
Pipeline execution risk and upcoming regulatory decisions could temper upside.
Background
RBC Capital Markets launched coverage on five European pharma companies, assigning ratings and price targets.
Ticker impact
AstraZeneca received Outperform rating and a 14,500 pence price target.
Possible 8-12% rally if market re-rates.
Analysts view current price as overly punished, expecting re-rating.
Novartis started coverage at Sector Perform with a 120 CHF target.
Limited move, likely within +/-3% range.
Sector Perform suggests no immediate catalyst, but target provides guidance.
GSK given Sector Perform rating and a 1,975 pence target.
Sideways trading expected.
Rating reflects current expectations already priced in.
Sanofi started coverage at Sector Perform with an 80 euro target.
Small range-bound movement.
Analysts see limited near-term catalysts.
Market effects
European pharma sector may see broader re-rating as coverage expands.
Potential modest uplift for European pharma stocks in EU markets.
Limited global impact; primarily affects European pharma investors.
Counterpoint
Some investors may view the neutral ratings as a sign of overvaluation risk.
Key entities
- financial_institutionRBC Capital Markets
Initiated coverage and set price targets.
